2- (4- (4- chlorobenzoyl)phenoxy)- 2- methylpropanoic acid

05/01/2009 - "Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study."
02/15/2009 - "This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia. "
01/01/2009 - "Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study."
02/15/2009 - "Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia."
02/15/2009 - "In conclusion, ABT-335 + atorvastatin combination therapy resulted in more effective control of multiple lipid parameters than either monotherapy and may be an appropriate therapy for patients with mixed dyslipidemia."

12/01/2013 - "Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome."
12/01/2013 - "ABT-335 therapy reduced fasting and postprandial triglycerides in patients with metabolic syndrome. "
12/01/2013 - "Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu(++)-mediated oxidation in patients with metabolic syndrome. "

12/01/2013 - "Postprandial lipemia was reduced with ABT-335 as demonstrated by a 28.5% reduction (p < 0.0005) in incremental area under the curve for TG during the 6-h period after the meal challenge. "
12/01/2013 - "Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu(++)-mediated oxidation in patients with metabolic syndrome. "